Tissue factor-deficiency and protease activated receptor-1-deficiency reduce inflammation elicited by diet-induced steatohepatitis in mice

American Journal of Pathology

Volumn 176, Issue 1, 2010, Pages 177-186

  Luyendyk, James P ^a   Sullivan, Bradley P ^a   Guo, Grace L ^a   Wang, Ruipeng ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; CHOLINE; CYCLOOXYGENASE 2; FIBRINOGEN; MACROPHAGE INFLAMMATORY PROTEIN 2; METHIONINE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DIET; DISEASE COURSE; ENZYME ACTIVITY; FIBRIN DEPOSITION; FIBRINOGEN BLOOD LEVEL; GENE EXPRESSION; GENE INDUCTION; INFLAMMATION; LIPID LIVER LEVEL; LIPID STORAGE; LIVER CELL DAMAGE; MACROPHAGE; MALE; MOUSE; NEUTROPHIL; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; WILD TYPE;

EID: 73949128483     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.090672     Document Type: Article

References (59)

1. Clark JM, Brancati FL, Diehl AM: Nonalcoholic fatty liver disease. Gastroenterology 2002, 122:1649-1657
2. Larter CZ, Yeh MM: Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 2008, 23:1635-1648
3. Farrell GC, Larter CZ: Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43:S99-S112
4. Kleiner DE, Brunt EM, Van NM, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321
5. Friedman SL: Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-1669
6. Koppe SW, Sahai A, Malladi P, Whitington PF, Green RM: Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J Hepatol 2004, 41:592-598
7. Sahai A, Malladi P, Melin-Aldana H, Green RM, Whitington PF: Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am J Physiol Gastrointest Liver Physiol 2004, 287:G264-G273
8. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM: Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007, 45:1366-1374
9. Dela Pena A, Leclercq I, Field J, George J, Jones B, Farrell G: NFkappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology 2005, 129:1663-1674
10. Yu J, Ip E, Dela PA, Hou JY, Sesha J, Pera N, Hall P, Kirsch R, Leclercq I, Farrell GC: COX-2 induction in mice with experimental nutritional steatohepatitis: role as pro-inflammatory mediator. Hepatology 2006, 43:826-836
11. Ip E, Farrell G, Hall P, Robertson G, Leclercq I: Administration of the potent PPARalpha agonist, Wy-14643, reverses nutritional fibrosis and steatohepatitis in mice Hepatology 2004, 39:1286-1296
12. Nagasawa T, Inada Y, Nakano S, Tamura T, Takahashi T, Maruyama K, Yamazaki Y, Kuroda J, Shibata N: Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 2006, 536:182-191
13. Schattenberg JM, Singh R, Wang Y, Lefkowitch JH, Rigoli RM, Scherer PE, Czaja MJ: JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 2006, 43:163-172
14. Northup PG, Sundaram V, Fallon MB, Reddy KR, Balogun RA, Sanyal AJ, Anstee QM, Hoffman MR, Ikura Y, Caldwell SH: Hypercoagulation and thrombophilia in liver disease. J Thromb Haemost 2008, 6:2-9
15. Alessi MC, Juhan-Vague I: Metabolic syndrome, haemostasis, and thrombosis. Thromb Haemost 2008, 99:995-1000
16. Cigolini M, Targher G, Agostino G, Tonoli M, Muggeo M, De SG: Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men-role of the metabolic syndrome. Thromb Haemost 1996, 76:69-73
17. Kotronen A, Yki-Jarvinen H: Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:27-38
18. Mackman N, Tilley RE, Key NS: Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2007, 27:1687-1693
19. Luyendyk JP, Cantor GH, Kirchhofer D, Mackman N, Copple BL, Wang R: Tissue factor-dependent coagulation contributes to alphanaphthylisothiocyanate- induced cholestatic liver injury in mice. Am J Physiol Gastrointest Liver Physiol 2009, 296:G840-G849
20. Mackman N, Sawdey MS, Keeton MR, Loskutoff DJ: Murine tissue factor gene expression in vivo: Tissue and cell specificity and regulation by lipopolysaccharide. Am J Pathol 1993, 143:76-84
21. Abiru S, Migita K, Maeda Y, Daikoku M, Ito M, Ohata K, Nagaoka S, Matsumoto T, Takii Y, Kusumoto K, Nakamura M, Komori A, Yano K, Yatsuhashi H, Eguchi K, Ishibashi H: Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 2006, 26:39-45
22. Farhadi A, Gundlapalli S, Shaikh M, Frantzides C, Harrell L, Kwasny MM, Keshavarzian A: Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int 2008, 28:1026-1033
23. Haukeland JW, Damas JK, Konopski Z, Loberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjoro K, Aukrust P: Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006, 44:1167-1174
24. Kudo H, Takahara T, Yata Y, Kawai K, Zhang W, Sugiyama T: Lipopolysaccharide triggered TNF-alpha-induced hepatocyte apoptosis in a murine non-alcoholic steatohepatitis model. J Hepatol 2009, 51:168-175
25. Coughlin SR: How the protease thrombin talks to cells. Proc Natl Acad Sci USA: 1999, 96:11023-11027
26. Copple BL, Moulin F, Hanumegowda UM, Ganey PE, Roth RA: Thrombin and protease-activated receptor-1 agonists promote lipopolysaccharide-induced hepatocellular injury in perfused livers. J Pharmacol Exp Ther 2003, 305:417-425
27. Cunningham MA, Rondeau E, Chen X, Coughlin SR, Holdsworth SR, Tipping PG: Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. J Exp Med 2000, 191:455-461
28. Olman MA, Mackman N, Gladson CL, Moser KM, Loskutoff DJ: Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest 1995, 96:1621-1630
29. Sevastos J, Kennedy SE, Davis DR, Sam M, Peake PW, Charlesworth JA, Mackman N, Erlich JH: Tissue factor deficiency and PAR-1 deficiency are protective against renal ischaemia reperfusion injury. Blood 2007, 109:577-583
30. Parry GCN, Erlich JH, Carmeliet P, Luther T, Mackman N: Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest 1998, 101:560-569
31. Connolly AJ, Suh DY, Hunt TK, Coughlin SR: Mice lacking the thrombin receptor. PAR1, have normal skin wound healing. Am J Pathol 1997, 151:1199-1204
32. Ganey PE, Luyendyk JP, Newport SW, Eagle TM, Maddox JF, Mackman N, Roth RA: Role of the coagulation system in acetaminophen-induced hepatotoxicity in mice. Hepatology 2007, 46:1177-1186
33. Tanaka Y, Aleksunes LM, Yeager RL, Gyamfi MA, Esterly N, Guo GL, Klaassen CD: NF-E2-related factor 2 inhibits lipid accumulation and oxidative stress in mice fed a high-fat diet. J Pharmacol Exp Ther 2008, 325:655-664
34. Weiler-Guettler H, Christie PD, Beeler DL, Healy AM, Hancock WW, Rayburn H, Edelberg JM, Rosenberg RD: A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest 1998, 101:1983-1991
35. Gaca MD, Zhou X, Benyon RC: Regulation of hepatic stellate cell proliferation and collagen synthesis by proteinase-activated receptors. J Hepatol 2002, 36:362-369
36. Stephenne X, Vosters O, Najimi M, Beuneu C, Dung KN, Wijns W, Goldman M, Sokal EM: Tissue factor-dependent procoagulant activity of isolated human hepatocytes: relevance to liver cell transplantation. Liver Transpl 2007, 13:599-606
37. Fiorucci S, Antonelli E, Distrutti E, Severino B, Fiorentina R, Baldoni M, Caliendo G, Santagada V, Morelli A, Cirino G: PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology 2004, 39:365-375
38. Mochida S, Arai M, Ohno A, Yamanobe F, Ishikawa K, Matsui A, Maruyama I, Kato H, Fujiwara K: Deranged blood coagulation equilibrium as a factor of massive liver necrosis following endotoxin administration in partially hepatectomized rats. Hepatology 1999, 29:1532-1540
39. Mackman N: Regulation of tissue factor gene expression in human monocytic and endothelial cells. Haemostasis 1996, 26:17-20
40. Schwertz H, Tolley ND, Foulks JM, Denis MM, Risenmay BW, Buerke M, Tilley RE, Rondina MT, Harris EM, Kraiss LW, Mackman N, Zimmerman GA, Weyrich AS: Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets. J Exp Med 2006, 203:2433-2440
41. Edens MA, Kuipers F, Stolk RP: Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obes Rev 2009, 10:412-419
42. Greco D, Kotronen A, Westerbacka J, Puig O, Arkkila P, Kiviluoto T, Laitinen S, Kolak M, Fisher RM, Hamsten A, Auvinen P, Yki-Jarvinen H: Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol 2008, 294:G1281-G1287
43. Yao ZM, Vance DE: The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes. J Biol Chem 1988, 263:2998-3004
44. Esmon CT: The interactions between inflammation and coagulation. Br J Haematol 2005, 131:417-430
45. Kudo H, Takahara T, Yata Y, Kawai K, Zhang W, Sugiyama T: Lipopolysaccharide triggered TNF-alpha-induced hepatocyte apoptosis in a murine non-alcoholic steatohepatitis model. J Hepatol 2009, 51:168-75
46. Koca SS, Bahcecioglu IH, Poyrazoglu OK, Ozercan IH, Sahin K, Ustundag B: The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Inflammation 2008, 31:91-98
47. Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, Kitamura N, Toda K, Kaneko T, Horie Y, Han JY, Kato S, Shimoda M, Oike Y, Tomizawa M, Makino S, Ohkura T, Saito H, Kumagai N, Nagata H, Ishii H, Hibi T: Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006, 55:415-424
48. Yu J, Wu CW, Chu ES, Hui AY, Cheng AS, Go MY, Ching AK, Chui YL, Chan HL, Sung JJ: Elucidation of the role of COX-2 in liver fibrogenesis using transgenic mice. Biochem Biophys Res Commun 2008, 372:571-577
49. Nocito A, Dahm F, Jochum W, Jang JH, Georgiev P, Bader M, Renner EL, Clavien PA: Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis. Gastroenterology 2007, 133:608-618
50. Ikura Y, Ohsawa M, Suekane T, Fukushima H, Itabe H, Jomura H, Nishiguchi S, Inoue T, Naruko T, Ehara S, Kawada N, Arakawa T, Ueda M: Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. Hepatology 2006, 43:506-514
51. Dambach DM, Watson LM, Gray KR, Durham SK, Laskin DL: Role of CCR2 in macrophage migration into the liver during acetaminopheninduced hepatotoxicity in the mouse. Hepatology 2002, 35:1093-1103
52. Hildebrand F, Hubbard WJ, Choudhry MA, Frink M, Pape HC, Kunkel SL, Chaudry IH: Kupffer cells and their mediators: the culprits in producing distant organ damage after trauma-hemorrhage. Am J Pathol 2006, 169:784-794
53. Hokeness KL, Kuziel WA, Biron CA, Salazar-Mather TP: Monocyte chemoattractant protein-1 and CCR2 interactions are required for IFN-alpha/beta-induced inflammatory responses and antiviral defense in liver. J Immunol 2005, 174:1549-1556
54. Kuziel WA, Morgan SJ, Dawson TC, Griffin S, Smithies O, Ley K, Maeda N: Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2 (gene targeting/monocyte chemoattractant protein 1/trafficking/peritonitis/ granuloma). Proc Natl Acad Sci USA: 1997, 94:12053-12058
55. Marra F, DeFranco R, Grappone C, Milani S, Pastacaldi S, Pinzani M, Romanelli RG, Laffi G, Gentilini P: Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol 1998, 152:423-430
56. Rizki G, Arnaboldi L, Gabrielli B, Yan J, Lee GS, Ng RK, Turner SM, Badger TM, Pitas RE, Maher JJ: Mice fed a lipogenic methioninecholine-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1. J Lipid Res 2006, 47:2280-2290
57. DeLeve LD, Wang X, Kanel GC, Atkinson R, McCuskey RS: Prevention of hepatic fibrosis in a murine model of metabolic syndrome with non-alcoholic steatohepatitis. Am J Pathol 2008, 173:993-1001
58. Xu ZJ, Fan JG, Ding XD, Qiao L, Wang GL: Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats. Dig Dis Sci 2009, doi: 10.1007/s10620-009-0815-3
59. Samad F, Pandey M, Loskutoff DJ: Regulation of tissue factor gene expression in obesity. Blood 2001, 98:3353-3358